

## DIVI'S LABORATORIES LIMITED

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2017

(₹. in Lakhs)

	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Revenue from operations</b>	<b>103788</b>	89020	97648	<b>274928</b>	299910	406577
<b>2</b>	Other Income	<b>1701</b>	3359	2171	<b>6431</b>	5505	7598
<b>3</b>	<b>Total Revenue from Operations (1+2)</b>	<b>105489</b>	92379	99819	<b>281359</b>	305415	414175
<b>4</b>	<b>Expenses</b>						
	a) Cost of materials consumed	<b>40853</b>	31352	34546	<b>104357</b>	112699	156319
	b) Purchases of stock-in-trade	<b>0</b>	0	0	<b>0</b>	0	0
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(15)</b>	4378	516	<b>5370</b>	(644)	(2161)
	d) Employee benefits expense	<b>11498</b>	10482	10340	<b>32050</b>	38423	49031
	e) Depreciation and amortization expense	<b>3739</b>	3393	3095	<b>10363</b>	9182	12326
	f) Finance Costs	<b>26</b>	75	44	<b>150</b>	121	225
	g) Other Expenses	<b>18838</b>	15088	14490	<b>46738</b>	41856	59612
	<b>Total expenses</b>	<b>74939</b>	64768	63031	<b>199028</b>	201637	275352
<b>5</b>	<b>Profit before exceptional Items and tax (3-4)</b>	<b>30550</b>	27611	36788	<b>82331</b>	103778	138823
<b>6</b>	Exceptional items	<b>0</b>	0	0	<b>0</b>	0	0
<b>7</b>	<b>Profit before Tax (5-6)</b>	<b>30550</b>	27611	36788	<b>82331</b>	103778	138823
<b>8</b>	Tax Expense						
	a) Current Tax	<b>6081</b>	5544	7517	<b>16452</b>	23771	28523
	b) Deferred Tax	<b>2003</b>	1389	2439	<b>5081</b>	609	4973
	<b>Total Tax Expense</b>	<b>8084</b>	6933	9956	<b>21533</b>	24380	33496
<b>9</b>	<b>Net Profit for the period (7-8)</b>	<b>22466</b>	20678	26832	<b>60798</b>	79398	105327
<b>10</b>	Other Comprehensive Income: Items that will not be reclassified to Profit or Loss: - Remeasurement of post-employment benefit obligation (net of tax)	<b>(37)</b>	(38)	(30)	<b>(111)</b>	(160)	(140)
<b>11</b>	<b>Total comprehensive Income for the period (9+10)</b>	<b>22429</b>	20640	26802	<b>60687</b>	79238	105187
<b>12</b>	Paid-up Equity Share Capital (Face Value: ₹. 2 per share)	<b>5309</b>	5309	5309	<b>5309</b>	5309	5309
<b>13</b>	Other Equity						535582
<b>14</b>	<b>Earnings per Share (of ₹. 2/- each) (not annualized)</b>						
	a) Basic	<b>8.46</b>	7.79	10.11	<b>22.90</b>	29.91	39.68
	b) Diluted	<b>8.46</b>	7.79	10.11	<b>22.90</b>	29.91	39.68



*(Handwritten Signature)*



**NOTES:**

1. The above results, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 27<sup>th</sup> January, 2018.
2. Results for the quarter ended 31<sup>st</sup> December 2017 were subjected to 'limited review' by the Auditors and their report contains no qualification.
3. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
4. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
6. The company's Unit-II at Visakhapatnam was inspected by the US-FDA from 11th September 2017 to 19th September 2017. US-FDA has issued Establishment Inspection Report (EIR) for the same.
7. Post implementation of Goods and Service Tax (GST) effective from 1st July, 2017, revenue is reported net of GST as per Ind AS 18. Revenue, however, is reported inclusive of excise duty for the current and previous periods. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

	Quarter ended			Nine Months ended		Year ended
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
<b>Revenue from operations (net of excise duty)</b>	<b>103788</b>	<b>88752</b>	96305	<b>273803</b>	296531	402386

8. Details of forex gain/(loss) are given below:

	Quarter ended			Nine Months ended		Year ended
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
<b>Forex gain/(loss)</b>	<b>(1597)</b>	1059	65	<b>163</b>	(1006)	(3910)

Forex gain has been included in Other Income and loss has been included in Other Expenses.

9. Figures for the previous periods/year have been regrouped/reclassified wherever necessary.

Place: Hyderabad  
Date: 27<sup>th</sup> January, 2018



for Divi's Laboratories Limited

*Murali K. Divi*  
Dr. Murali K. Divi  
Chairman & Managing Director

